Moderna
American biotechnology company
Follow Moderna on Notably News to receive short updates to your email — rarely!
| 2025 | The Montreal vaccine factory is scheduled to begin supplying COVID-19 vaccines. |
| 2024 | Projected further decline in financial performance, with expected revenue of $3,200 million and a projected net loss of $3,600 million, suggesting continued market challenges. |
| November 2024 | Moderna announced that Stéphane Bancel will step down from his role as Chief Commercial Officer while remaining CEO. Stephen Hoge will take over responsibilities for the company's sales, medical, and research affairs. |
| November 2024 | GlaxoSmithKline (GSK) filed a lawsuit against Moderna Inc. in a U.S. federal court in Delaware, alleging patent infringement related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV vaccine mResvia. The lawsuit claims Moderna's use of lipid nanoparticles violates GSK's patents for mRNA delivery innovations. |
| May 2024 | The mRNA vaccine Mresvia was approved by the US Food and Drug Administration (FDA) for preventing lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years and older. |
| April 2024 | A court issued an order that strengthened Arbutus Biopharma's arguments in the patent dispute with Moderna. |
| 2023 | Moderna experiences a financial downturn, with revenue dropping to $6,848 million and returning to a net loss of $4,710 million, indicating challenges in sustaining pandemic-era growth. |
| 2023 | Moderna acquired OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, in its first acquisition. |
| 2023 | In collaboration with Merck, Moderna won breakthrough status from the FDA for its mRNA-4157/V940 drug candidate, a cancer vaccine. |
| July 2023 | Moderna entered into an agreement with the Chinese government to develop mRNA drugs for exclusive use in China. |
| April 2023 | A court affirmed a decision to cancel a patent by Arbutus Biopharma in a patent infringement lawsuit against Moderna. |
| February 2023 | Moderna agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research to settle a dispute over a chemical technique used in the vaccine. |
| 2022 | FDA approved Moderna's monovalent vaccine, Spikevax, and a bivalent booster. |
| 2022 | Moderna maintains strong financial performance with $19,263 million in revenue and a net income of $8,362 million, continuing to benefit from COVID-19 vaccine distribution. |
| April 2022 | Moderna announced plans to build a $180 million vaccine factory in Montreal, forming a 10-year partnership with the Government of Canada, Quebec, and McGill University to produce 100 million Spikevax doses annually. |
| 2021 | Moderna experiences significant financial breakthrough, reporting $18,471 million in revenue and a substantial net income of $12,202 million, primarily due to COVID-19 vaccine sales. |
| 2020 | COVID-19 pandemic year: Moderna's revenue surges to $803 million, with a net loss of $747 million, likely driven by vaccine development efforts. |
| 2020 | Moderna received $955 million from Operation Warp Speed to accelerate COVID-19 vaccine development, with a total commitment of $4.9 billion for producing 300 million vaccine doses. |
| December 2020 | Moderna's COVID-19 vaccine (mRNA-1273) received emergency use authorization in the United States. |
| March 2020 | The Food and Drug Administration approved clinical trials for the Moderna COVID-19 vaccine candidate. |
| 2019 | Moderna reports modest revenue of $60 million and a net loss of $514 million, indicating an early-stage biotechnology company. |
| 2019 | Moderna developed its first antibody encoded by mRNA. |
| December 2018 | Moderna became a public company through the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share. |
| July 2018 | Moderna opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical, and clinical work. |
| January 2016 | The Bill & Melinda Gates Foundation committed to provide at least $20 million in grant funding to Moderna. The company also formed a partnership with Vertex Pharmaceuticals to develop treatments for cystic fibrosis. |
| 2015 | Moderna formed a partnership with Merck & Co. to develop cancer treatments and developed its first mRNA vaccine for influenza. |
| January 2015 | Moderna launched Valera, a venture focusing on viral, bacterial, and parasitic infectious diseases, with employees developing an mRNA vaccine candidate against Zika virus infection. |
| January 14 2014 | Moderna announced the creation of Onkaido Therapeutics, a venture focused exclusively on developing mRNA-based oncology treatments. |
| 2013 | Moderna formed a partnership with AstraZeneca to develop treatments for cardiovascular, metabolic, renal diseases, and cancer, and was awarded a $25 million DARPA grant to develop an mRNA vaccine capable of suppressing a global pandemic within 60 days. |
| 2011 | Moderna began raising venture capital funding, eventually collecting $2 billion between 2011 and 2017. |
| 2011 | Stéphane Bancel was appointed as CEO of Moderna. |
| 2010 | Moderna was founded by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. |
This contents of the box above is based on material from the Wikipedia article Moderna, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.